Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia
Colin D. Godwin, Olivia M. Bates, Sae Rin Jean, George S. Laszlo, Eliotte E. Garling, Mary E. Beddoe, Michael H. Cardone, Roland B. Walter
Abstract
Over 26,000 people will face a new diagnosis of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in 2020 in the U.S. alone, and only a minority will be long-term survivors [1]. Am...
Topics & Concepts
CalicheamicinMyeloid leukemiaMedicineGemtuzumab ozogamicinDrug resistanceLeukemiaLymphoblastic LeukemiaCancer researchAntibody-drug conjugateAntibodyDrugApoptosisAcute leukemiaImmunologyOncologyMonoclonal antibodyPharmacologyBiologyCD33Stem cellGeneticsCD34Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchRetinoids in leukemia and cellular processes